Titre : Profilage d'ADN

Profilage d'ADN : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Profilage d'ADN : Questions médicales les plus fréquentes", "headline": "Profilage d'ADN : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Profilage d'ADN : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-01", "dateModified": "2025-03-28", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Profilage d'ADN" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Identification biométrique", "url": "https://questionsmedicales.fr/mesh/D056667", "about": { "@type": "MedicalCondition", "name": "Identification biométrique", "code": { "@type": "MedicalCode", "code": "D056667", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N04.452.910.099" } } }, "about": { "@type": "MedicalCondition", "name": "Profilage d'ADN", "alternateName": "DNA Fingerprinting", "code": { "@type": "MedicalCode", "code": "D016172", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Saqer S Alotaibi", "url": "https://questionsmedicales.fr/author/Saqer%20S%20Alotaibi", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Giuseppe Mannino", "url": "https://questionsmedicales.fr/author/Giuseppe%20Mannino", "affiliation": { "@type": "Organization", "name": "Plant Physiology Unit, Department of Life Sciences and Systems Biology, University of Turin, Via Quarello 15/a, 10135 Turin, Italy. giuseppe.mannino@unito.it." } }, { "@type": "Person", "name": "Massimo E Maffei", "url": "https://questionsmedicales.fr/author/Massimo%20E%20Maffei", "affiliation": { "@type": "Organization", "name": "Plant Physiology Unit, Department of Life Sciences and Systems Biology, University of Turin, Via Quarello 15/a, 10135 Turin, Italy. massimo.maffei@unito.it." } }, { "@type": "Person", "name": "Na Tian", "url": "https://questionsmedicales.fr/author/Na%20Tian", "affiliation": { "@type": "Organization", "name": "College of Traditional Chinese Medicine, Guangdong Pharmaceutical University Guangzhou 510006, China State Key Laboratory of Dao-di Herbs Breeding Base, National Resource Center for Chinese Materia Medica,China Academy of Chinese Medical Sciences Beijing 100700, China." } }, { "@type": "Person", "name": "Tian Zhang", "url": "https://questionsmedicales.fr/author/Tian%20Zhang", "affiliation": { "@type": "Organization", "name": "State Key Laboratory of Dao-di Herbs Breeding Base, National Resource Center for Chinese Materia Medica,China Academy of Chinese Medical Sciences Beijing 100700, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Progressive Paracentral Visual Field Loss at Low Intraocular Pressures Following LASIK.", "datePublished": "2024-06-14", "url": "https://questionsmedicales.fr/article/39141409", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002395" } }, { "@type": "ScholarlyArticle", "name": "Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers.", "datePublished": "2022-08-02", "url": "https://questionsmedicales.fr/article/35939832", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002092" } }, { "@type": "ScholarlyArticle", "name": "Correlation between Interocular Asymmetry of Corneal Hysteresis and Visual Field Defect in Glaucoma.", "datePublished": "2023-02-09", "url": "https://questionsmedicales.fr/article/36758563", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3341/kjo.2022.0120" } }, { "@type": "ScholarlyArticle", "name": "Comparing the Accuracy of Peripapillary OCT Scans and Visual Fields to Detect Glaucoma Worsening.", "datePublished": "2023-02-06", "url": "https://questionsmedicales.fr/article/36754173", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ophtha.2023.01.021" } }, { "@type": "ScholarlyArticle", "name": "Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS).", "datePublished": "2022-10-10", "url": "https://questionsmedicales.fr/article/36228777", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajo.2022.09.011" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Administration des services de santé", "item": "https://questionsmedicales.fr/mesh/D006298" }, { "@type": "ListItem", "position": 3, "name": "Organisation et administration", "item": "https://questionsmedicales.fr/mesh/D009934" }, { "@type": "ListItem", "position": 4, "name": "Mesures de sécurité", "item": "https://questionsmedicales.fr/mesh/D012637" }, { "@type": "ListItem", "position": 5, "name": "Identification biométrique", "item": "https://questionsmedicales.fr/mesh/D056667" }, { "@type": "ListItem", "position": 6, "name": "Profilage d'ADN", "item": "https://questionsmedicales.fr/mesh/D016172" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Profilage d'ADN - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Profilage d'ADN", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Profilage d'ADN", "description": "Comment le profilage d'ADN est-il utilisé dans le diagnostic ?\nQuels échantillons sont nécessaires pour le profilage d'ADN ?\nLe profilage d'ADN peut-il aider à identifier des maladies héréditaires ?\nLe profilage d'ADN est-il fiable ?\nPeut-on utiliser le profilage d'ADN pour des tests de parenté ?", "url": "https://questionsmedicales.fr/mesh/D016172?mesh_terms=Visual+Field+Tests&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Profilage d'ADN", "description": "Quels symptômes peuvent indiquer un besoin de profilage d'ADN ?\nLe profilage d'ADN peut-il révéler des anomalies génétiques ?\nY a-t-il des symptômes psychologiques liés à l'utilisation de l'ADN ?\nLe profilage d'ADN peut-il aider à diagnostiquer des maladies ?\nQuels impacts émotionnels le profilage d'ADN peut-il avoir ?", "url": "https://questionsmedicales.fr/mesh/D016172?mesh_terms=Visual+Field+Tests&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Profilage d'ADN", "description": "Le profilage d'ADN peut-il aider à la prévention des maladies ?\nComment le profilage d'ADN est-il utilisé en santé publique ?\nLe profilage d'ADN peut-il influencer le mode de vie ?\nY a-t-il des programmes de prévention basés sur le profilage d'ADN ?\nLe profilage d'ADN est-il accessible pour la prévention ?", "url": "https://questionsmedicales.fr/mesh/D016172?mesh_terms=Visual+Field+Tests&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Profilage d'ADN", "description": "Le profilage d'ADN est-il utilisé pour des traitements médicaux ?\nComment le profilage d'ADN influence-t-il les traitements ?\nLe profilage d'ADN peut-il prédire l'efficacité d'un traitement ?\nY a-t-il des traitements spécifiques basés sur le profilage d'ADN ?\nLe profilage d'ADN est-il utilisé dans la recherche de nouveaux traitements ?", "url": "https://questionsmedicales.fr/mesh/D016172?mesh_terms=Visual+Field+Tests&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Profilage d'ADN", "description": "Quelles complications peuvent survenir avec le profilage d'ADN ?\nLe profilage d'ADN peut-il entraîner des erreurs d'identification ?\nY a-t-il des risques de confidentialité avec le profilage d'ADN ?\nLe profilage d'ADN peut-il causer des conflits familiaux ?\nQuelles sont les implications légales du profilage d'ADN ?", "url": "https://questionsmedicales.fr/mesh/D016172?mesh_terms=Visual+Field+Tests&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Profilage d'ADN", "description": "Quels facteurs influencent la nécessité de profilage d'ADN ?\nLe profilage d'ADN est-il plus fréquent dans certaines populations ?\nLes antécédents médicaux influencent-ils le profilage d'ADN ?\nY a-t-il des facteurs environnementaux liés au profilage d'ADN ?\nLe mode de vie affecte-t-il le besoin de profilage d'ADN ?", "url": "https://questionsmedicales.fr/mesh/D016172?mesh_terms=Visual+Field+Tests&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment le profilage d'ADN est-il utilisé dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Il permet d'identifier des individus dans des enquêtes criminelles ou des tests de paternité." } }, { "@type": "Question", "name": "Quels échantillons sont nécessaires pour le profilage d'ADN ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des échantillons de sang, de salive ou de cheveux peuvent être utilisés." } }, { "@type": "Question", "name": "Le profilage d'ADN peut-il aider à identifier des maladies héréditaires ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut révéler des prédispositions génétiques à certaines maladies." } }, { "@type": "Question", "name": "Le profilage d'ADN est-il fiable ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est considéré comme très fiable avec un faible taux d'erreur." } }, { "@type": "Question", "name": "Peut-on utiliser le profilage d'ADN pour des tests de parenté ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est couramment utilisé pour établir des liens de parenté." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un besoin de profilage d'ADN ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de symptômes physiques, mais des situations légales ou familiales peuvent l'exiger." } }, { "@type": "Question", "name": "Le profilage d'ADN peut-il révéler des anomalies génétiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Indirectement, il peut indiquer des risques génétiques, mais ce n'est pas son but principal." } }, { "@type": "Question", "name": "Y a-t-il des symptômes psychologiques liés à l'utilisation de l'ADN ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des résultats inattendus peuvent causer du stress ou de l'anxiété chez les individus." } }, { "@type": "Question", "name": "Le profilage d'ADN peut-il aider à diagnostiquer des maladies ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Il peut aider à identifier des prédispositions, mais ne diagnostique pas directement des maladies." } }, { "@type": "Question", "name": "Quels impacts émotionnels le profilage d'ADN peut-il avoir ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Il peut provoquer des révélations sur l'identité ou des liens familiaux, entraînant des émotions fortes." } }, { "@type": "Question", "name": "Le profilage d'ADN peut-il aider à la prévention des maladies ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut identifier des risques génétiques, permettant des mesures préventives." } }, { "@type": "Question", "name": "Comment le profilage d'ADN est-il utilisé en santé publique ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il aide à surveiller les maladies génétiques et à planifier des interventions de santé." } }, { "@type": "Question", "name": "Le profilage d'ADN peut-il influencer le mode de vie ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les résultats peuvent inciter à adopter des comportements plus sains." } }, { "@type": "Question", "name": "Y a-t-il des programmes de prévention basés sur le profilage d'ADN ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Certaines initiatives de santé utilisent le profilage pour cibler des populations à risque." } }, { "@type": "Question", "name": "Le profilage d'ADN est-il accessible pour la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'accès varie selon les pays et les systèmes de santé, mais il devient plus courant." } }, { "@type": "Question", "name": "Le profilage d'ADN est-il utilisé pour des traitements médicaux ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Non, il n'est pas un traitement, mais peut guider des décisions thérapeutiques." } }, { "@type": "Question", "name": "Comment le profilage d'ADN influence-t-il les traitements ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il peut aider à choisir des traitements adaptés en fonction des prédispositions génétiques." } }, { "@type": "Question", "name": "Le profilage d'ADN peut-il prédire l'efficacité d'un traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il peut indiquer comment un patient réagira à certains médicaments." } }, { "@type": "Question", "name": "Y a-t-il des traitements spécifiques basés sur le profilage d'ADN ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Certains traitements ciblés en oncologie utilisent des informations génétiques." } }, { "@type": "Question", "name": "Le profilage d'ADN est-il utilisé dans la recherche de nouveaux traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est essentiel pour identifier des cibles thérapeutiques dans la recherche." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le profilage d'ADN ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications éthiques et psychologiques peuvent survenir, comme la stigmatisation." } }, { "@type": "Question", "name": "Le profilage d'ADN peut-il entraîner des erreurs d'identification ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Bien que rare, des erreurs peuvent se produire, entraînant des conséquences juridiques." } }, { "@type": "Question", "name": "Y a-t-il des risques de confidentialité avec le profilage d'ADN ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la confidentialité des données génétiques est une préoccupation majeure." } }, { "@type": "Question", "name": "Le profilage d'ADN peut-il causer des conflits familiaux ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des résultats inattendus peuvent révéler des secrets familiaux, entraînant des tensions." } }, { "@type": "Question", "name": "Quelles sont les implications légales du profilage d'ADN ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Il peut soulever des questions juridiques concernant la propriété des données et l'utilisation." } }, { "@type": "Question", "name": "Quels facteurs influencent la nécessité de profilage d'ADN ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'hérédité, l'histoire familiale et des enquêtes criminelles peuvent influencer." } }, { "@type": "Question", "name": "Le profilage d'ADN est-il plus fréquent dans certaines populations ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines populations peuvent être plus souvent testées en raison de prédispositions génétiques." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le profilage d'ADN ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies peuvent justifier un profilage d'ADN." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux liés au profilage d'ADN ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs environnementaux peuvent interagir avec des prédispositions génétiques, influençant la santé." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il le besoin de profilage d'ADN ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie à risque peut inciter à un profilage pour évaluer des risques génétiques." } } ] } ] }

Sources (10000 au total)

Smoking Cessation May Reduce Risk of Visual Field Progression in Heavy Smokers.

The earlier a person quits smoking the more likely is the optic nerve be spared from damage.... To investigate the effect of smoking cessation on visual field (VF) progression in glaucoma.... Primary open angle glaucoma patients with a minimum of 3 years follow-up and 5 VFs were included. Linear mixed models were used to investigate the effects of smoking on the rates of 24-2 VF mean devia... Five hundred eleven eyes of 354 patients were included over the mean follow-up of 12.4 years. Mean baseline age (95% confidence interval) was 62.3 (61.2, 63.4) years. One hundred forty nine (42.1%) pa... After ≥25 years of smoking cessation, the risk of VF progression in former heavy smokers becomes similar to never smokers. Long-term smoking cessation may be associated with lower VF progression in gl...

Correlation between Interocular Asymmetry of Corneal Hysteresis and Visual Field Defect in Glaucoma.

To evaluate the relationship between interocular asymmetries of corneal hysteresis (CH) and visual field defects in Korean patients with glaucoma.... A total of 444 eyes from 222 participants with glaucoma in at least one eye were enrolled. CH was measured using an ocular response analyzer (Reichert Technologies Inc). Eyes of each participant were ... Median (interquartile range) MD value was -3.71 dB (-6.87 to -1.30 dB) in the better eye and -10.20 dB (-16.32 to -5.62 dB) in the worse eye. When the correlation between the asymmetry of the MD value... The interocular asymmetry of CH was significantly correlated with the interocular asymmetry of visual field defects in glaucoma....

Comparing the Accuracy of Peripapillary OCT Scans and Visual Fields to Detect Glaucoma Worsening.

To compare the accuracy of detecting moderate and rapid rates of glaucoma worsening over a 2-year period with different numbers of OCT scans and visual field (VF) tests in a large sample of glaucoma a... Descriptive and simulation study.... The OCT sample comprised 12 150 eyes from 7392 adults with glaucoma or glaucoma suspect status followed up at the Wilmer Eye Institute from 2013 through 2021. The VF sample comprised 20 583 eyes from ... Within-eye rates of change in retinal nerve fiber layer (RNFL) thickness and mean deviation (MD) were measured using linear regression. For each measured rate, simulated measurements of RNFL thickness... The accuracy of diagnosing moderate and rapid rates of glaucoma worsening for different numbers of OCT scans and VF tests over a 2-year period.... Accuracy was less than 50% for both OCT and VF when diagnosing worsening after a 2-year period. OCT accuracy was 5 to 10 percentage points higher than VF accuracy at detecting moderate worsening and 1... More frequent OCT scans and VF tests are needed to improve the accuracy of diagnosing glaucoma worsening. Accuracy greatly increases when relying on both OCT and VF to detect worsening.... The author(s) have no proprietary or commercial interest in any materials discussed in this article....

Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS).

to compare visual field (VF) progression between the 2 arms of the Treatment of Advanced Glaucoma Study (TAGS).... Post hoc analysis of VF data from a 2-arm, multicenter, randomized controlled clinical trial.... A total of 453 patients with newly diagnosed advanced open-angle glaucoma in at least 1 eye from 27 centers in the United Kingdom were randomized to either trabeculectomy (n = 227) or medication in th... This study analyzed 211 eyes in the trabeculectomy first arm and 203 eyes in the medication first arm. The average RoP (estimate [95% credible intervals]) was -0.59 [-0.88, -0.31] dB/year in the medic... There was no significant difference in the average RoP at 2 years....

Visual Field Endpoints for Neuroprotective Trials: A Case for AI-Driven Patient Enrichment.

To evaluate whether an artificial intelligence (AI) model can better select candidates that would demonstrate visual field (VF) progression, in order to shorten the duration or the number of patients ... Retrospective cohort study.... 7428 eyes of 3871 patients from the University of Washington Department of Ophthalmology VF Dataset were included. Progression was defined as at least 5 locations with >7 dB of change compared with ba... A total of 13% of all patients met the criteria for progression at 5 years. Differences in survival were observed when stratified by MD and age (P < .0001). Those at risk of progression included patie... An AI model can identify high-risk patients to substantially reduce the number of patients needed or study duration required to meet clinical trial endpoints....

Fast Progressors in Glaucoma: Prevalence Based on Global and Central Visual Field Loss.

To determine the prevalence of fast global and central visual field (VF) progression in individuals with glaucoma under routine care.... Observational study.... Six hundred ninety-three eyes of 461 individuals with glaucoma followed up over a median of 4.5 years.... This study included (1) patients at a private ophthalmology clinic in Melbourne, Australia, and (2) individuals in 2 prospective longitudinal observational studies across 3 sites in the United States.... Prevalence of progression based on the rate of MD and the MTD... Based on the MD and the MTD... This study found that approximately 1 in 8 eyes with glaucoma receiving routine care showed fast progression based on global MD values (< -1.0 dB/year) and that nearly 1 in 3 eyes showed a < -0.5 dB/y... Proprietary or commercial disclosure may be found after the references....

Accuracy of Visual Fields in Localizing MRI Lesions in Posterior Cerebral Artery Infarction.

The representation of the visual field in visual cortex was established over a century ago by correlating perimetric defects with the estimated location of war wounds. The availability of high-definit... Homonymous hemianopias disclosed on automated visual fields (HVFs) were drawn from an electronic medical record search from 2009 to 2020 at the Michigan Medicine, a tertiary care academic medical cent... Among the 77 VFDs confined to 1 hemifield, 74 (96%) correctly predicted the side of the visual cortex lesion. In 3 cases, the MRI lesion in the opposite cerebral hemisphere was not foretold. Among the... In this study of PCA ischemic stroke, VFDs limited to 1 hemifield were accurate in locating the side and quadrant of the MRI visual cortex lesions. However, the quadrantic VFDs sometimes failed to pre...

Baseline 10-2 Visual Field Loss as a Predictor for Future Glaucoma Progression.

Presence of baseline 10-2 visual field (VF) loss was the strongest predictor of future rate of 24-2 VF loss and development of new 24-2 progression events, suggesting a role for 10-2 VF testing in bas... The purpose of this study is to examine the relationship between baseline 10-2 VF loss and future 24-2 VF loss.... Subjects were participating in a prospective longitudinal study within a VA Medical Center outpatient eye clinic. Eligibility required 2 good quality baseline 10-2 VF tests followed by a minimum of 5 ... We studied 394 eyes of 202 subjects (119 primary open angle glaucoma and 83 glaucoma suspect). Over 6.7 (±1.5) years, 9.9 (±2.3) good quality 24-2 VF tests were completed. In mixed model regression an... Baseline 10-2 VF defect was the most effective predictor of subsequent 24-2 VF progression in this study. These findings imply that presence of baseline 10-2 VF loss may provide unique value for predi...